Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/hepatitis C co-infected cohorts

PLoS ONE

Volumn 4, Issue 2, 2009, Pages

  Moodie, Erica E M ^a   Pai, Nitika Pant ^b   Klein, Marina B ^b  

^a MCGILL UNIVERSITY   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EXPOSURE; FEMALE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DISEASE; LIVER FAILURE; LIVER FIBROSIS; LIVER TOXICITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; THROMBOCYTE COUNT; TREATMENT DURATION;

HEPATITIS C VIRUS;

EID: 84887212517     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004517     Document Type: Article

References (37)

1. Hogg RS, Yip B, Kully C, Craib KJ, O'Shaughnessy MV, et al. (1999) Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. Cmaj 160: 659-665.
2. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853-860.
3. Bica I, McGovern B, Dhar R, Stone D, McGowan K, et al. (2001) Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 32: 492-497.
4. Macias J, Melguizo I, Fernandez-Rivera FJ, Garcia-Garcia A, Mira JA, et al. (2002) Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected patients receiving potent antiretroviral therapy. Eur J Clin Microbiol Infect Dis 21: 775-781.
5. Rosenthal E, Pialoux G, Rey D, Karmochkine M, Pompidou G, et al. Liver-related mortality in human immunodeficiency virus-infected patients in France (GERMIVIC cohort study, 1995-2003); October 29-November 2, 2004; Boston, MA, pp Abstract 572.
6. Salmon-Ceron D, Lewden C, Morlat P, Bevilacqua S, Jougla E, et al. (2005) Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 42: 799-805.
7. Selik RM, Byers RH Jr, Dworkin MS (2002) Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999. J Acquir Immune Defic Syndr 29: 378-387.
8. Tatsunami S, Taki M, Shirahata A, Mimaya J, Yamada K (2004) Increasing incidence of critical liver disease among causes of death in Japanese hemophiliacs with HIV-1. Acta Haematol 111: 181-184.
9. Zylberberg H, Pialoux G, Carnot F, Landau A, Brechot C, et al. (1998) Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy. Clin Infect Dis 27: 1255-1258.
10. (May, 2005) HIV/AIDS Epi Updates. Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Public Health Agency of Canada.
11. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, et al. (2001) Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 33: 562-569.
12. Sanchez-Quijano A, Andreu J, Gavilan F, Luque F, Abad MA, et al. (1995) Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis 14: 949-953.
13. Soto B, Sanchez-Quijano A, Rodrigo L, del Olmo JA, Garcia-Bengoechea M, et al. (1997) Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 26: 1-5.
14. Sulkowski MS, Mehta SH, Torbenson M, Afdhal NH, Mirel L, et al. (2005) Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. Aids 19: 585-592.
15. Benhamou Y, Di Martino V, Bochet M, Colombet G, Thibault V, et al. (2001) Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 34: 283-287.
16. Macias J, Castellano V, Merchante N, Palacios RB, Mira JA, et al. (2004) Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. Aids 18: 767-774.
17. Marine-Barjoan E, Saint-Paul MC, Pradier C, Chaillou S, Anty R, et al. (2004) Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/ hepatitis C virus co-infected patients. Aids 18: 2163-2170.
18. Fuster D, Planas R, Muga R, Ballesteros AL, Santos J, et al. (2004) Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy. AIDS Res Hum Retroviruses 20: 1293-1297.
19. Mehta SH, Thomas DL, Torbenson M, Brinkley S, Mirel L, et al. (2005) The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology 41: 123-131.
20. Al-Mohri H, Cooper C, Murphy T, Klein MB (2005) Validation of a simple model for predicting liver fibrosis in HIV/hepatitis C virus-coinfected patients. HIV Med 6: 375-378.
21. Nunes D, Fleming C, Offner G, O'Brien M, Tumilty S, et al. (2005) HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immune Defic Syndr 40: 538-544.
22. Kelleher TB, Mehta SH, Bhaskar R, Sulkowski M, Astemborski J, et al. (2005) Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol 43: 78-84.
23. Al-Mohri H, Murphy T, Lu Y, Lalonde RG, Klein MB (2007) Evaluating Liver Fibrosis Progression and the Impact of Antiretroviral Therapy in HIV and Hepatitis C Coinfection Using a Noninvasive Marker. J Acquir Immune Defic Syndr 44: 463-469.
24. Murphy DG, Cote L, Fauvel M, Rene P, Vincelette J (2000) Multicenter comparison of Roche COBAS AMPLICOR MONITOR version 1.5, Organon Teknika NucliSens QT with Extractor, and Bayer Quantiplex version 3.0 for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 38: 4034-4041.
25. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, et al. (2003) A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38: 518-526.
26. Hirano K, Imbens G (2004) The Propensity Score with Continuous Treatments. In: Gelman A, Meng X, eds. Applied Bayesian Modeling and Causal Inference from Incomplete-Data Perspectives. New York: John Wiley.
27. Imbens GW (2000) The role of the propensity score in estimating dose-response functions. Biometrika 87: 706-710.
28. Yasui H, Adachi M, Imai K (2003) Combination of tumor necrosis factor-alpha with sulindac in human carcinoma cells in vivo. Ann N Y Acad Sci 1010: 273-277.
29. Box GEP, Cox DR (1964) An analysis of transformations. Journal of the Royal Statistical Society Series B 26: 211-246.
30. Robins J (1997) Causal Inference from Complex Longitudinal Data. Latent Variable Modeling and Applications to Causality. New York: Springer-Verlang.
31. Robins JM, Hernan MA, Brumback B (2000) Marginal structural models and causal inference in epidemiology. Epidemiology 11: 550-560.
32. Maharaj B, Maharaj RJ, Leary WP, Cooppan RM, Naran AD, et al. (1986) Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1: 523-525.
33. Bedossa P, Dargere D, Paradis V (2003) Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38: 1449-1457.
34. Thomas D. Staging liver disease in HIV/HCV co-infected persons: is liver biopsy the right test?; 2007 February 25-28; Los Angeles, CA, pp Abstract 161.
35. Sterling R, Lissen E, Clumeck N, Sola R, Correa M, et al. Can routine noninvasive tests predict liver histology in HIV/HCV co-infection? Analysis of patients entering the AIDS PEGASYS Ribavirin International Co-infection Trial (APRICOT); 2005 February; Boston.
36. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, et al. (2001) Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357: 1069-1075.
37. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, et al. (2002) Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 36: 986-992.